Preparation of Vitamin E-Containing High-Density Lipoprotein and Its Protective Efficacy on Macrophages
Atherosclerosis is a major cause for cardiovascular diseases. High-density lipoprotein (HDL) may reduce atherosclerosis through several different mechanisms. HDL is composed of lipids, cholesterol, cholesteryl esters, triglycerides, and phospholipids, mainly phosphatidylcholine plus specialized proteins called apolipoproteins (apos). In this study, we prepared vitamin E containing HDL (VE-HDL) that contains egg phosphatidylcholine, cholesterol, vitamin E, and two kinds of recombinant human apolipoproteins (rhapo)-rhapoA-I and rhapoE in vitro by the facilitation of cholate. After that, we studied the effects of VE-HDL on foam cell formation, cellular cholesterol efflux, oxidative low-density lipoprotein (oxLDL)-stimulated oxidative stress, and apoptosis of macrophages to evaluate the protective efficacy of VE-HDL on macrophages. As the results showed, we prepared a new type of reconstituent HDL with apolipoproteins and vitamin E for the first time. VE-HDL has protective efficacy on macrophages. It has the prospect of becoming a therapeutic agent on atherosclerosis in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Assay and drug development technologies - 16(2018), 2 vom: 02. Feb., Seite 107-114 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Manman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-18-4 |
|---|
| Anmerkungen: |
Date Completed 28.10.2019 Date Revised 28.10.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/adt.2017.831 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281278237 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281278237 | ||
| 003 | DE-627 | ||
| 005 | 20231225031250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/adt.2017.831 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0937.xml |
| 035 | |a (DE-627)NLM281278237 | ||
| 035 | |a (NLM)29469589 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Manman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation of Vitamin E-Containing High-Density Lipoprotein and Its Protective Efficacy on Macrophages |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2019 | ||
| 500 | |a Date Revised 28.10.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Atherosclerosis is a major cause for cardiovascular diseases. High-density lipoprotein (HDL) may reduce atherosclerosis through several different mechanisms. HDL is composed of lipids, cholesterol, cholesteryl esters, triglycerides, and phospholipids, mainly phosphatidylcholine plus specialized proteins called apolipoproteins (apos). In this study, we prepared vitamin E containing HDL (VE-HDL) that contains egg phosphatidylcholine, cholesterol, vitamin E, and two kinds of recombinant human apolipoproteins (rhapo)-rhapoA-I and rhapoE in vitro by the facilitation of cholate. After that, we studied the effects of VE-HDL on foam cell formation, cellular cholesterol efflux, oxidative low-density lipoprotein (oxLDL)-stimulated oxidative stress, and apoptosis of macrophages to evaluate the protective efficacy of VE-HDL on macrophages. As the results showed, we prepared a new type of reconstituent HDL with apolipoproteins and vitamin E for the first time. VE-HDL has protective efficacy on macrophages. It has the prospect of becoming a therapeutic agent on atherosclerosis in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a apolipoprotein | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a reconstituent HDL | |
| 650 | 4 | |a vitamin E | |
| 650 | 7 | |a Lipoproteins, HDL |2 NLM | |
| 650 | 7 | |a Vitamin E |2 NLM | |
| 650 | 7 | |a 1406-18-4 |2 NLM | |
| 700 | 1 | |a Wang, Dingding |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Weiqin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lixian |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Manhua |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Tianmin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Assay and drug development technologies |d 2002 |g 16(2018), 2 vom: 02. Feb., Seite 107-114 |w (DE-627)NLM14784164X |x 1557-8127 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:2 |g day:02 |g month:02 |g pages:107-114 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/adt.2017.831 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 2 |b 02 |c 02 |h 107-114 | ||